Heart Failure Reviews

, Volume 11, Issue 4, pp 313–323 | Cite as

Magnetic resonance imaging in the evaluation of non-ischemic cardiomyopathies: Current applications and future perspectives

  • Ilan Gottlieb
  • Robson Macedo
  • David A. Bluemke
  • João A. C. Lima


Patients with non-ischemic cardiomyopathy often represent a diagnostic challenge, and correct etiologic diagnosis may influence outcomes. Lately, delayed myocardial enhancement MR imaging has been developed and is currently being used for a growing number of clinical applications. On delayed enhancement MR images, scarring or fibrosis appears as an area of high signal intensity, and the pattern by which this enhancement occurs in the myocardium allows distinction of many different pathologies. In nonischemic cardiomyopathy, the delayed enhancement usually does not occur in a coronary artery distribution and is often midwall rather than subendocardial or transmural. It could also guide myocardial biopsy to an affected area, increasing its yield. Cardiac magnetic resonance imaging has now a definitive role in clinical practice, and its capability to non-invasively provide high resolution images of the heart with good tissue characterization is redefining the understanding of the conditions that can adversely affect the myocardium.


Cardiomyopathy Magnetic resonance Imaging Non-invasive 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996;93(5):841–42.PubMedGoogle Scholar
  2. 2.
    Doughan AR, Williams BR. Cardiac sarcoidosis. Heart 2006;92(2):282–8.PubMedGoogle Scholar
  3. 3.
    Zieman SJ, Fortuin NJ. Hypertrophic and restrictive cardiomyopathies in the elderly. Cardiol Clin 1999;17(1):159–72, ix.PubMedGoogle Scholar
  4. 4.
    Kubo N, Morimoto S, Hiramitsu S, et al. Feasibility of diagnosing chronic myocarditis by endomyocardial biopsy. Heart Vessels 1997;12(4):167–70.PubMedGoogle Scholar
  5. 5.
    Arbustini E, Gavazzi A, Dal Bello B, et al. Ten-year experience with endomyocardial biopsy in myocarditis presenting with congestive heart failure: frequency, pathologic characteristics, treatment and follow-up. G Ital Cardiol 1997;27(3):209–23.PubMedGoogle Scholar
  6. 6.
    Lima JA, Desai MY. Cardiovascular magnetic resonance imaging: current and emerging applications. J Am Coll Cardiol 2004;44(6):1164–71.PubMedGoogle Scholar
  7. 7.
    Budoff MJ, Cohen MC, Garcia MJ, et al. ACCF/AHA clinical competence statement on cardiac imaging with computed tomography and magnetic resonance: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training. J Am Coll Cardiol 2005;46(2):383–402.PubMedGoogle Scholar
  8. 8.
    Azevedo CF, Cheng S, Lima JA. Cardiac imaging to identify patients at risk for developing heart failure after myocardial infarction. Curr Heart Fail Rep 2005;2(4):183–8.PubMedGoogle Scholar
  9. 9.
    Lima JA, Judd RM, Bazille A, Schulman SP, Atalar E, Zerhouni EA. Regional heterogeneity of human myocardial infarcts demonstrated by contrast-enhanced MRI. Potential mechanisms. Circulation 1995;92(5):1117–25.PubMedGoogle Scholar
  10. 10.
    Wu KC, Lima JA. Noninvasive imaging of myocardial viability: current techniques and future developments. Circ Res 2003;93(12):1146–58.PubMedGoogle Scholar
  11. 11.
    Felker GM, Shaw LK, O’Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 2002;39(2):210–8.PubMedGoogle Scholar
  12. 12.
    Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996;94(11):2807–16.PubMedGoogle Scholar
  13. 13.
    Pennell DJ, Underwood SR, Ell PJ, Swanton RH, Walker JM, Longmore DB. Dipyridamole magnetic resonance imaging: a comparison with thallium-201 emission tomography. Br Heart J 1990;64(6):362–9.PubMedGoogle Scholar
  14. 14.
    Pennell DJ, Underwood SR, Manzara CC, et al. Magnetic resonance imaging during dobutamine stress in coronary artery disease. Am J Cardiol 1992;70(1):34–40.PubMedGoogle Scholar
  15. 15.
    Baer FM, Voth E, Theissen P, Schicha H, Sechtem U. Gradient-echo magnetic resonance imaging during incremental dobutamine infusion for the localization of coronary artery stenoses. Eur Heart J 1994;15(2):218–25.PubMedGoogle Scholar
  16. 16.
    van Rugge FP, Van Der Wall EE, de Roos A, Bruschke AV. Dobutamine stress magnetic resonance imaging for detection of coronary artery disease. J Am Coll Cardiol 1993;22(2):431–9.PubMedGoogle Scholar
  17. 17.
    Pennell DJ. Magnetic resonance imaging during pharmacologic stress. Coron Artery Dis 1993;4(4):345–53.PubMedGoogle Scholar
  18. 18.
    van Rugge FP, Van Der Wall EE, Spanjersberg SJ, et al. Magnetic resonance imaging during dobutamine stress for detection and localization of coronary artery disease. Quantitative wall motion analysis using a modification of the centerline method. Circulation 1994;90(1):127–38.PubMedGoogle Scholar
  19. 19.
    Manning WJ, Atkinson DJ, Grossman W, Paulin S, Edelman RR. First-pass nuclear magnetic resonance imaging studies using gadolinium-DTPA in patients with coronary artery disease. J Am Coll Cardiol 1991;18(4):959–65.PubMedGoogle Scholar
  20. 20.
    Wendland MF, Saeed M, Masui T, Derugin N, Moseley ME, Higgins CB. Echo-planar MR imaging of normal and ischemic myocardium with gadodiamide injection. Radiology 1993;186(2):535–42.PubMedGoogle Scholar
  21. 21.
    Saeed M, Wendland MF, Yu KK, et al. Identification of myocardial reperfusion with echo planar magnetic resonance imaging. Discrimination between occlusive and reperfused infarctions. Circulation 1994;90(3):1492–1501.PubMedGoogle Scholar
  22. 22.
    Schaefer S, van Tyen R, Saloner D. Evaluation of myocardial perfusion abnormalities with gadolinium-enhanced snapshot MR imaging in humans. Work in progress. Radiology 1992;185(3):795–801.PubMedGoogle Scholar
  23. 23.
    Manning WJ, Li W, Boyle NG, Edelman RR. Fat-suppressed breath-hold magnetic resonance coronary angiography. Circulation 1993;87(1):94–104.PubMedGoogle Scholar
  24. 24.
    Duerinckx AJ, Urman MK. Two-dimensional coronary MR angiography: analysis of initial clinical results. Radiology 1994;193(3):731–8.PubMedGoogle Scholar
  25. 25.
    Manning WJ, Li W, Edelman RR. A preliminary report comparing magnetic resonance coronary angiography with conventional angiography. N Engl J Med 1993;328(12):828–32.PubMedGoogle Scholar
  26. 26.
    Pennell DJ, Bogren HG, Keegan J, Firmin DN, Underwood SR. Assessment of coronary artery stenosis by magnetic resonance imaging. Heart 1996;75(2):127–33.PubMedGoogle Scholar
  27. 27.
    Post JC, van Rossum AC, Hofman MB, Valk J, Visser CA. Three-dimensional respiratory-gated MR angiography of coronary arteries: comparison with conventional coronary angiography. AJR Am J Roentgenol 1996;166(6):1399–1404.PubMedGoogle Scholar
  28. 28.
    Edelman RR, Manning WJ, Gervino E, Li W. Flow velocity quantification in human coronary arteries with fast, breath-hold MR angiography. J Magn Reson Imaging 1993;3(5):699–703.PubMedGoogle Scholar
  29. 29.
    Poncelet BP, Weisskoff RM, Wedeen VJ, Brady TJ, Kantor H. Time of flight quantification of coronary flow with echo-planar MRI. Magn Reson Med 1993;30(4):447–57.PubMedGoogle Scholar
  30. 30.
    Clarke GD, Eckels R, Chaney C, et al. Measurement of absolute epicardial coronary artery flow and flow reserve with breath-hold cine phase-contrast magnetic resonance imaging. Circulation 1995;91(10):2627–34.PubMedGoogle Scholar
  31. 31.
    Hundley WG, Lange RA, Clarke GD, et al. Assessment of coronary arterial flow and flow reserve in humans with magnetic resonance imaging. Circulation 1996;93(8):1502–8.PubMedGoogle Scholar
  32. 32.
    Wu KC, Kim RJ, Bluemke DA, et al. Quantification and time course of microvascular obstruction by contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial infarction and reperfusion. J Am Coll Cardiol 1998;32(6):1756–64.PubMedGoogle Scholar
  33. 33.
    Bello D, Shah DJ, Farah GM, et al. Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation 2003;108(16):1945–53.PubMedGoogle Scholar
  34. 34.
    Schuster EH, Bulkley BH. Ischemic cardiomyopathy: a clinicopathologic study of fourteen patients. Am Heart J 1980;100(4):506–12.PubMedGoogle Scholar
  35. 35.
    Roberts WC, Siegel RJ, McManus BM. Idiopathic dilated cardiomyopathy: analysis of 152 necropsy patients. Am J Cardiol 1987;60(16):1340–55.PubMedGoogle Scholar
  36. 36.
    Koenig SH, Spiller M, Brown RD, 3rd, Wolf GL. Relaxation of water protons in the intra- and extracellular regions of blood containing Gd(DTPA). Magn Reson Med 1986;3(5):791–5.PubMedGoogle Scholar
  37. 37.
    Kim RJ, Judd RM, Chen EL, Fieno DS, Parrish TB, Lima JA. Relationship of elevated 23Na magnetic resonance image intensity to infarct size after acute reperfused myocardial infarction. Circulation 1999;100(2):185–92.PubMedGoogle Scholar
  38. 38.
    Rehwald WG, Fieno DS, Chen EL, Kim RJ, Judd RM. Myocardial magnetic resonance imaging contrast agent concentrations after reversible and irreversible ischemic injury. Circulation 2002;105(2):224–9.PubMedGoogle Scholar
  39. 39.
    Wu E, Judd RM, Vargas JD, Klocke FJ, Bonow RO, Kim RJ. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet 2001;357(9249):21–8.PubMedGoogle Scholar
  40. 40.
    McCrohon JA, Moon JC, Prasad SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 2003;108(1):54–9.PubMedGoogle Scholar
  41. 41.
    Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000;101(5):570–80.PubMedGoogle Scholar
  42. 42.
    Arroyo LH, Lee RT. Mechanisms of plaque rupture: mechanical and biologic interactions. Cardiovasc Res 1999;41(2):369–75.PubMedGoogle Scholar
  43. 43.
    Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003;42(9):1687–1713.PubMedGoogle Scholar
  44. 44.
    Devlin AM, Moore NR, Ostman-Smith I. A comparison of MRI and echocardiography in hypertrophic cardiomyopathy. Br J Radiol 1999;72(855):258–64.PubMedGoogle Scholar
  45. 45.
    Moon JC, Fisher NG, McKenna WJ, Pennell DJ. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart 2004;90(6):645–9.PubMedGoogle Scholar
  46. 46.
    Rickers C, Wilke NM, Jerosch-Herold M, et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 2005;112(6):855–61.PubMedGoogle Scholar
  47. 47.
    Choudhury L, Mahrholdt H, Wagner A, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;40(12):2156–64.PubMedGoogle Scholar
  48. 48.
    Maron BJ. The paradox of exercise. N Engl J Med 2000;343 (19):1409–11.PubMedGoogle Scholar
  49. 49.
    Varnava AM, Elliott PM, Mahon N, Davies MJ, McKenna WJ. Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol 2001;88(3):275–9.PubMedGoogle Scholar
  50. 50.
    Teraoka K, Hirano M, Ookubo H, et al. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. Magn Reson Imaging 2004;22(2):155–61.PubMedGoogle Scholar
  51. 51.
    Pennell DJ, Sechtem UP, Higgins CB, et al. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. Eur Heart J 2004;25(21):1940–65.PubMedGoogle Scholar
  52. 52.
    White RD, Obuchowski NA, Gunawardena S, et al. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: presurgical and postsurgical evaluation by computed tomography magnetic resonance imaging. Am J Card Imaging 1996;10(1):1–13.PubMedGoogle Scholar
  53. 53.
    Sievers B, Moon JC, Pennell DJ. Images in cardiovascular Medicine. Magnetic resonance contrast enhancement of iatrogenic septal myocardial infarction in hypertrophic cardiomyopathy. Circulation 2002;105(8):1018.PubMedGoogle Scholar
  54. 54.
    van Dockum WG, ten Cate FJ, ten Berg JM, et al. Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging. J Am Coll Cardiol 2004;43(1):27–34.PubMedGoogle Scholar
  55. 55.
    Crilley JG, Boehm EA, Blair E, et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 2003;41(10):1776–82.PubMedGoogle Scholar
  56. 56.
    Dong SJ, MacGregor JH, Crawley AP, et al. Left ventricular wall thickness and regional systolic function in patients with hypertrophic cardiomyopathy. A three-dimensional tagged magnetic resonance imaging study. Circulation 1994;90(3):1200–9.PubMedGoogle Scholar
  57. 57.
    Kramer CM, Reichek N, Ferrari VA, Theobald T, Dawson J, Axel L. Regional heterogeneity of function in hypertrophic cardiomyopathy. Circulation 1994;90(1):186–94.PubMedGoogle Scholar
  58. 58.
    Young AA, Kramer CM, Ferrari VA, Axel L, Reichek N. Three-dimensional left ventricular deformation in hypertrophic cardiomyopathy. Circulation 1994;90(2):854–67.PubMedGoogle Scholar
  59. 59.
    Reichek N. MRI myocardial tagging. J Magn Reson Imaging 1999;10(5):609–16.PubMedGoogle Scholar
  60. 60.
    Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. N Engl J Med 1997;336(4):267–76.PubMedGoogle Scholar
  61. 61.
    Masui T, Finck S, Higgins CB. Constrictive pericarditis and restrictive cardiomyopathy: evaluation with MR imaging. Radiology 1992;182(2):369–73.PubMedGoogle Scholar
  62. 62.
    Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med 1998;339(6):364–9.PubMedGoogle Scholar
  63. 63.
    Marcus FI, Fontaine GH, Guiraudon G, et al. Right ventricular dysplasia: a report of 24 adult cases. Circulation 1982;65(2):384–98.PubMedGoogle Scholar
  64. 64.
    Tandri H, Friedrich MG, Calkins H, Bluemke DA. MRI of arrhythmogenic right ventricular cardiomyopathy/dysplasia. J Cardiovasc Magn Reson 2004;6(2):557–63.PubMedGoogle Scholar
  65. 65.
    Blake LM, Scheinman MM, Higgins CB. MR features of arrhythmogenic right ventricular dysplasia. AJR Am J Roentgenol 1994;162(4):809–12.PubMedGoogle Scholar
  66. 66.
    Midiri M, Finazzo M. MR imaging of arrhythmogenic right ventricular dysplasia. Int J Cardiovasc Imaging 2001;17(4):297–304.PubMedGoogle Scholar
  67. 67.
    Tandri H, Saranathan M, Rodriguez ER, et al. Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J Am Coll Cardiol 2005;45(1):98–103.PubMedGoogle Scholar
  68. 68.
    Corrado D, Leoni L, Link MS, et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 2003;108(25):3084–91.PubMedGoogle Scholar
  69. 69.
    Desai MY, Gupta S, Bomma C, et al. The apparent inversion time for optimal delayed enhancement magnetic resonance imaging differs between the right and left ventricles. J Cardiovasc Magn Reson 2005;7(2):475–9.PubMedGoogle Scholar
  70. 70.
    Burke AP, Farb A, Tashko G, Virmani R. Arrhythmogenic right ventricular cardiomyopathy and fatty replacement of the right ventricular myocardium: are they different diseases? Circulation 1998;97(16):1571–80.PubMedGoogle Scholar
  71. 71.
    Fontaine G, Fontaliran F, Zenati O, et al. Fat in the heart. A feature unique to the human species? Observational reflections on an unsolved problem. Acta Cardiol 1999;54(4):189–94.PubMedGoogle Scholar
  72. 72.
    Tandri H, Bluemke DA, Ferrari VA, et al. Findings on magnetic resonance imaging of idiopathic right ventricular outflow tachycardia. Am J Cardiol 2004;94(11):1441–5.PubMedGoogle Scholar
  73. 73.
    Grimm W, List-Hellwig E, Hoffmann J, et al. Magnetic resonance imaging and signal-averaged electrocardiography in patients with repetitive monomorphic ventricular tachycardia and otherwise normal electrocardiogram. Pacing Clin Electrophysiol 1997;20(7):1826–33.PubMedGoogle Scholar
  74. 74.
    White RD, Trohman RG, Flamm SD, et al. Right ventricular arrhythmia in the absence of arrhythmogenic dysplasia: MR imaging of myocardial abnormalities. Radiology 1998;207(3):743–51.PubMedGoogle Scholar
  75. 75.
    Proclemer A, Basadonna PT, Slavich GA, Miani D, Fresco C, Fioretti PM. Cardiac magnetic resonance imaging findings in patients with right ventricular outflow tract premature contractions. Eur Heart J 1997;18(12):2002–10.PubMedGoogle Scholar
  76. 76.
    Globits S, Kreiner G, Frank H, et al. Significance of morphological abnormalities detected by MRI in patients undergoing successful ablation of right ventricular outflow tract tachycardia. Circulation 1997;96(8):2633–40.PubMedGoogle Scholar
  77. 77.
    Ladich E, Virmani R, Burke A. Sudden cardiac death not related to coronary atherosclerosis. Toxicol Pathol 2006;34(1):52–7.PubMedGoogle Scholar
  78. 78.
    Shanes JG, Ghali J, Billingham ME, et al. Interobserver variability in the pathologic interpretation of endomyocardial biopsy results. Circulation 1987;75(2):401–5.PubMedGoogle Scholar
  79. 79.
    Hauck AJ, Kearney DL, Edwards WD. Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error. Mayo Clin Proc 1989;64(10):1235–45.PubMedGoogle Scholar
  80. 80.
    Davies RA, Veinot JP, Smith S, Struthers C, Hendry P, Masters R. Giant cell myocarditis: clinical presentation, bridge to transplantation with mechanical circulatory support, and long-term outcome. J Heart Lung Transplant 2002;21(6):674–9.PubMedGoogle Scholar
  81. 81.
    Scott RL, Ratliff NB, Starling RC, Young JB. Recurrence of giant cell myocarditis in cardiac allograft. J Heart Lung Transplant 2001;20(3):375–80.PubMedGoogle Scholar
  82. 82.
    Friedrich MG, Strohm O, Schulz-Menger J, Marciniak H, Luft FC, Dietz R. Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation 1998;97(18):1802–9.PubMedGoogle Scholar
  83. 83.
    Mahrholdt H, Goedecke C, Wagner A, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 2004;109(10):1250–8.PubMedGoogle Scholar
  84. 84.
    Shirani J, Freant LJ, Roberts WC. Gross and semiquantitative histologic findings in mononuclear cell myocarditis causing sudden death, and implications for endomyocardial biopsy. Am J Cardiol 1993;72(12):952–7.PubMedGoogle Scholar
  85. 85.
    Abdel-Aty H, Boye P, Zagrosek A, et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol 2005;45(11):1815–22.PubMedGoogle Scholar
  86. 86.
    Hagar JM, Rahimtoola SH. Chagas’ heart disease. Curr Probl Cardiol 1995;20(12):825–924.PubMedGoogle Scholar
  87. 87.
    Bellotti G, Bocchi EA, de Moraes AV, et al. In vivo detection of Trypanosoma cruzi antigens in hearts of patients with chronic Chagas’ heart disease. Am Heart J 1996;131(2):301–7.PubMedGoogle Scholar
  88. 88.
    Bestetti RB, Muccillo G. Clinical course of Chagas’ heart disease: a comparison with dilated cardiomyopathy. Int J Cardiol 1997;60(2):187–93.PubMedGoogle Scholar
  89. 89.
    de Paola AA, Gomes JA, Terzian AB, Miyamoto MH, Martinez Fo EE. Ventricular tachycardia during exercise testing as a predictor of sudden death in patients with chronic chagasic cardiomyopathy and ventricular arrhythmias. Br Heart J 1995;74(3):293–5.PubMedGoogle Scholar
  90. 90.
    Carrasco HA, Parada H, Guerrero L, Duque M, Duran D, Molina C. Prognostic implications of clinical, electrocardiographic and hemodynamic findings in chronic Chagas’ disease. Int J Cardiol 1994;43(1):27–38.PubMedGoogle Scholar
  91. 91.
    Kalil Filho R, de Albuquerque CP. Magnetic resonance imaging in Chagas’ heart disease. Sao Paulo Med J 1995;113(2):880–3.PubMedGoogle Scholar
  92. 92.
    Rochitte CE, Oliveira PF, Andrade JM, et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas’ disease: a marker of disease severity. J Am Coll Cardiol 2005;46(8):1553–8.PubMedGoogle Scholar
  93. 93.
    Shammas RL, Movahed A. Sarcoidosis of the heart. Clin Cardiol 1993;16(6):462–72.PubMedGoogle Scholar
  94. 94.
    Lewin RF, Mor R, Spitzer S, Arditti A, Hellman C, Agmon J. Echocardiographic evaluation of patients with systemic sarcoidosis. Am Heart J 1985;110(1 Pt 1):116–22.PubMedGoogle Scholar
  95. 95.
    Saeki M, Kitazawa H, Kodama M, et al. Images in cardiovascular medicine. Cardiac sarcoidosis. 67Ga imaging and histology. Circulation 1995;91(9):2497–8.PubMedGoogle Scholar
  96. 96.
    Ratner SJ, Fenoglio JJ, Jr, Ursell PC. Utility of endomyocardial biopsy in the diagnosis of cardiac sarcoidosis. Chest 1986;90(4):528–33.PubMedGoogle Scholar
  97. 97.
    Vignaux O, Dhote R, Duboc D, et al. Detection of myocardial involvement in patients with sarcoidosis applying T2-weighted, contrast-enhanced, and cine magnetic resonance imaging: initial results of a prospective study. J Comput Assist Tomogr 2002;26(5):762–7.PubMedGoogle Scholar
  98. 98.
    Kurashima K, Shimizu H, Ogawa H, et al. MR and CT in the evaluation of sarcoid myopathy. J Comput Assist Tomogr 1991;15(6):1004–7.PubMedGoogle Scholar
  99. 99.
    Vignaux O. Cardiac sarcoidosis: spectrum of MRI features. AJR Am J Roentgenol 2005;184(1):249–54.PubMedGoogle Scholar
  100. 100.
    Vignaux O, Dhote R, Duboc D, et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. Chest 2002;122(6):1895–1901.PubMedGoogle Scholar
  101. 101.
    Vignaux O. Cardiac sarcoidosis: spectrum of MRI features. AJR Am J Roentgenol 2005;184(1):249–54.PubMedGoogle Scholar
  102. 102.
    Kurashima K, Shimizu H, Ogawa H, et al. MR and CT in the evaluation of sarcoid myopathy. J Comput Assist Tomogr 1991;15(6):1004–7.PubMedGoogle Scholar
  103. 103.
    Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. N Engl J Med 1997;336(4):267–76.PubMedGoogle Scholar
  104. 104.
    Masui T, Finck S, Higgins CB. Constrictive pericarditis and restrictive cardiomyopathy: evaluation with MR imaging. Radiology 1992;182(2):369–73.PubMedGoogle Scholar
  105. 105.
    Francone M, Dymarkowski S, Kalantzi M, Rademakers FE, Bogaert J. Assessment of ventricular coupling with real-time cine MRI and its value to differentiate constrictive pericarditis from restrictive cardiomyopathy. Eur Radiol 2006;16(4):944–51.PubMedGoogle Scholar
  106. 106.
    Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349(6):583–96.PubMedGoogle Scholar
  107. 107.
    Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337(13):898–909.PubMedGoogle Scholar
  108. 108.
    Perugini E, Rapezzi C, Piva T, et al. Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 2006;92(3):343–9.PubMedGoogle Scholar
  109. 109.
    Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111(2):186–93.PubMedGoogle Scholar
  110. 110.
    Fattori R, Rocchi G, Celletti F, Bertaccini P, Rapezzi C, Gavelli G. Contribution of magnetic resonance imaging in the differential diagnosis of cardiac amyloidosis and symmetric hypertrophic cardiomyopathy. Am Heart J 1998;136(5): 824–30.PubMedGoogle Scholar
  111. 111.
    Friedrich MG. Magnetic resonance imaging in cardiomyopathies. Journal of Cardiovascular Magnetic Resonance: Official Journal of The Society For Cardiovascular Magnetic Resonance 2000;2(1):67–82.Google Scholar
  112. 112.
    Siegelman ES, Mitchell DG, Semelka RC. Abdominal iron deposition: metabolism, MR findings, and clinical importance. Radiology 1996/4;199(1):13–22.PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2006

Authors and Affiliations

  • Ilan Gottlieb
    • 1
  • Robson Macedo
    • 1
  • David A. Bluemke
    • 1
  • João A. C. Lima
    • 1
  1. 1.Division of Cardiology, Department of MedicineThe Johns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations